Evidence map›Paper›PMID 40927979›Full record

ArticleInternational journal of molecular medicine2025

Pharmacological inhibition of casein kinase II attenuates metaflammation in a murine model of diet‑induced metabolic dysfunction.

Elisa Porchietto, Eleonora Aimaretti, Giacomo Einaudi, Gustavo Ferreira Alves, Debora Collotta, Enrica Marzani, Leonardo Camillò, Chiara Rubeo, Raffaella Mastrocola, Natasha Irrera and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Elisa Porchietto *Pharmacology Unit, School of Pharmacy, University of Camerino, I‑62032 Camerino, Italy.
Eleonora Aimaretti *Department of Neurosciences 'Rita Levi Montalcini', University of Turin, I‑10125 Turin, Italy.
Giacomo EinaudiPharmacology Unit, School of Pharmacy, University of Camerino, I‑62032 Camerino, Italy.
Gustavo Ferreira AlvesPharmacology Unit, School of Pharmacy, University of Camerino, I‑62032 Camerino, Italy.
Debora CollottaDepartment of Neurosciences 'Rita Levi Montalcini', University of Turin, I‑10125 Turin, Italy.
Enrica MarzaniDepartment of Neurosciences 'Rita Levi Montalcini', University of Turin, I‑10125 Turin, Italy.
Leonardo CamillòDepartment of Neurosciences 'Rita Levi Montalcini', University of Turin, I‑10125 Turin, Italy.
Chiara RubeoDepartment of Clinical and Biological Sciences, University of Turin, I‑10125 Turin, Italy.
Raffaella MastrocolaDepartment of Clinical and Biological Sciences, University of Turin, I‑10125 Turin, Italy.
Natasha IrreraDepartment of Clinical and Experimental Medicine, University of Messina, I‑98125 Messina, Italy.
Manuela AragnoDepartment of Clinical and Biological Sciences, University of Turin, I‑10125 Turin, Italy.
Carlo Cifani *Pharmacology Unit, School of Pharmacy, University of Camerino, I‑62032 Camerino, Italy.
Massimo Collino *Department of Neurosciences 'Rita Levi Montalcini', University of Turin, I‑10125 Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kinases are activators of well‑known inflammatory cascades implicated in metabolic disorders, and abnormal activation of casein kinase II (CK2) is associated with several inflammatory disorders. However, thus far, its role in the low‑grade chronic inflammatory response known as 'metaflammation', which is a hallmark of obesity and type 2 diabetes, has not yet been elucidated. The present study aimed to evaluate the role of CK2 in diet‑induced metaflammation and the effects of the CK2 inhibitor 4,5,6,7‑tetrabromobenzotriazole (TBB) on a murine model fed a high‑fat‑high‑sugar (HFHS) diet. C57BL/6JOlaHsd mice were fed a standard diet (n=12) or HFHS diet (n=24) for 12 weeks. A subgroup of the HFHS group received TBB (2.5 mg/kg/day, orally, n=12) for the last 8 weeks. Subsequently, plasma and liver samples were harvested for

Indexed as

Casein Kinase IIDiet, High-FatInflammationMetabolic DiseasesProtein Kinase InhibitorsTriazolesAnimalsCytokinesDisease Models, AnimalLiverMaleMiceMice, Inbred C57BL4,5,6,7-tetrabromobenzotriazoleCasein Kinase IICytokinesProtein Kinase InhibitorsTriazolesCK2HFHS dietinflammationTBB

Identifiers

PMID40927979
PMCPMC12425356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.